Twist Bioscience Surges on Strong Q1 Results in Bioscience Innovation

ponzi_poet · 2026-02-17T12:10:48+00:00

Twist Bioscience Corp. shares rose 7% following improved Q1 results, showing a narrowed loss of $30.5 million and a revenue increase to $103.7 million, signaling operational progress and growing investor confidence in the bioscience sector.

ponzi_poet

2026-02-17 12:10:48

Abstract generation in progress

Shares of Twist Bioscience Corp. rallied approximately 7 percent in Monday morning trading, powered by the company’s first-quarter financial announcement that demonstrates meaningful operational improvement. The bioscience technology leader reported narrowed losses of $30.5 million, equivalent to $0.50 per share, a notable improvement from $31.6 million or $0.53 per share in the prior-year quarter. The stock, trading at $44.23 on Nasdaq—up $3.28 or 7.69 percent from Friday’s close of $41.07—reflects investor confidence in the company’s trajectory.

Improved Financial Performance Signals Momentum

The first quarter results underscore Twist Bioscience’s progress in reducing operational losses while maintaining growth. Revenue surged to $103.7 million, representing substantial top-line expansion compared to $88.7 million in the same period a year ago. This 16.9 percent revenue increase outpaces the loss reduction rate, suggesting the bioscience firm is moving toward profitability and operational efficiency.

Stock Performance and Market Positioning

Over the trailing twelve months, TWST has demonstrated considerable volatility, trading within a range of $23.30 to $54.74. The current rally positions the stock near its recent highs, reflecting renewed market enthusiasm for the bioscience sector’s growth prospects. The combination of improved financial metrics and revenue acceleration has renewed investor appetite for companies advancing innovation in DNA synthesis and molecular biology applications.

Disclaimer: This analysis reflects market observations and does not represent endorsement of any trading recommendation. Information based on RTTNews reporting and Nasdaq market data.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.